Omar Halawi/iStock via Getty Images I upgraded Becton, Dickinson and Company's (NYSE:BDX) to a 'Buy' rating in my previous article published in March 2024, arguing major growth challenges including Alaris pump and strong year-over-year comparables were fading away. I believe GLP-1 drug delivery could become a significant growth driver for the company in the near future. The company announced to acquire Edwards Lifesciences' (EW) Critical Care product group for $4.2 billion. I view the acquisition as value a ...